Neutrophil recruitment by intradermally injected neutrophil attractant/activation protein-1.

Neutrophil attractant/activation protein-1 (NAP-1) is a recently described cytokine that attracts neutrophils, but not monocytes or eosinophils. This leukocyte specificity is not absolute, in that NAP-1 attracts basophils and small numbers of lymphocytes. Our purpose was to determine in vivo effects of NAP-1, and to compare them to the reported action of the complement attractant, C5a. Intradermal injection into normal human subjects of 40 microliters of NAP-1, over a concentration range of 4 x 10(-8) M to 10(-6) M, caused no symptoms or signs such as wheal-and-flare, itching, induration, or tenderness. However, biopsies of injection sites showed perivascular neutrophil infiltration as early as 30 min, which increased at 1 and 3 h. The mean number of neutrophils per mm2 of dermis for 15 biopsies taken 3 h after intradermal injection of 2 x 10(-7) M or 10(-6) M NAP-1 was 164 +/- 41; the response to saline or a NAP-1 inactive fragment was 5 or less. Intradermal NAP-1 did not cause basophil or lymphocyte infiltration. Consistent with the absence of a wheal-and-flare, acid toluidine blue-stained sections showed no evidence of mast cell degranulation, in contrast to previously reported results with C5a. Thus, the predominant response by human subjects to intradermal NAP-1 was neutrophil accumulation in proximity to dermal blood vessels.

[1]  E. Leonard,et al.  Leukocyte specificity and binding of human neutrophil attractant/activation protein-1. , 1990, Journal of immunology.

[2]  J. Westwick,et al.  Potent and specific inhibition of IL-8-, IL-1α- and IL-1β-inducedin vitro human lymphocyte migration by calcium channel antagonists , 1989 .

[3]  B. Dewald,et al.  The neutrophil-activating peptide NAF/NAP-1 induces histamine and leukotriene release by interleukin 3-primed basophils , 1989, The Journal of experimental medicine.

[4]  K. Yancey,et al.  Inflammatory properties of human C5a and C5a des Arg/ in mast cell-depleted human skin. , 1989, Journal of Investigative Dermatology.

[5]  M. Yamada,et al.  Production and characterization of recombinant human neutrophil chemotactic factor. , 1989, Journal of biochemistry.

[6]  M. Kaliner,et al.  Neutrophil attractant/activation protein-1 (NAP-1) causes human basophil histamine release. , 1989, Immunology letters.

[7]  J. Van Damme,et al.  Granulocyte chemotactic protein/interleukin-8 induces plasma leakage and neutrophil accumulation in rabbit skin. , 1989, The American journal of pathology.

[8]  B. Dewald,et al.  In vivo inflammatory activity of neutrophil-activating factor, a novel chemotactic peptide derived from human monocytes. , 1989, The American journal of pathology.

[9]  E. Appella,et al.  The neutrophil-activating protein (NAP-1) is also chemotactic for T lymphocytes. , 1989, Science.

[10]  R. Strieter,et al.  Endothelial cell gene expression of a neutrophil chemotactic factor by TNF-alpha, LPS, and IL-1 beta. , 1989, Science.

[11]  J. Schröder,et al.  Secretion of novel and homologous neutrophil-activating peptides by LPS-stimulated human endothelial cells. , 1989, Journal of immunology.

[12]  E. Appella,et al.  Three forms of monocyte-derived neutrophil chemotactic factor (MDNCF) distinguished by different lengths of the amino-terminal sequence. , 1989, Molecular immunology.

[13]  E. Appella,et al.  Synthesis and biological characterization of monocyte‐derived neutrophil chemotactic factor , 1988, FEBS letters.

[14]  E. Appella,et al.  Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor , 1988, The Journal of experimental medicine.

[15]  B. Dewald,et al.  A novel neutrophil-activating factor produced by human mononuclear phagocytes , 1988, The Journal of experimental medicine.

[16]  J. van Beeumen,et al.  A novel, NH2-terminal sequence-characterized human monokine possessing neutrophil chemotactic, skin-reactive, and granulocytosis-promoting activity , 1988, The Journal of experimental medicine.

[17]  T. Herlin,et al.  Human monocyte and polymorphonuclear leukocyte chemotactic and chemokinetic responses to leukotriene B4 and FMLP. , 2009, Acta pathologica, microbiologica, et immunologica Scandinavica. Section C, Immunology.

[18]  E. Appella,et al.  Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[19]  J. Schröder,et al.  Purification and partial biochemical characterization of a human monocyte-derived, neutrophil-activating peptide that lacks interleukin 1 activity. , 1987, Journal of immunology.

[20]  E. Leonard,et al.  A series of six ligands for the human formyl peptide receptor: tetrapeptides with high chemotactic potency and efficacy. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[21]  K. Matsushima,et al.  Neutrophil chemotactic factor produced by lipopolysaccharide (LPS)-stimulated human blood mononuclear leukocytes: partial characterization and separation from interleukin 1 (IL 1). , 1987, Journal of immunology.

[22]  R. Cotran,et al.  Interleukin 1 acts on cultured human vascular endothelium to increase the adhesion of polymorphonuclear leukocytes, monocytes, and related leukocyte cell lines. , 1985, The Journal of clinical investigation.

[23]  K. Yancey,et al.  Studies of human C5a as a mediator of inflammation in normal human skin. , 1985, The Journal of clinical investigation.

[24]  H. Perez,et al.  Biologically active complement (C5)-derived peptides and their relevance to disease. , 1984, Critical reviews in oncology/hematology.

[25]  K. Frank Austen,et al.  Local Effects of Synthetic Leukotrienes (LTC4, LTD4, and LTB4) in Human Skin , 1983 .

[26]  R. Snyderman,et al.  Molecular and cellular mechanisms of leukocyte chemotaxis. , 1981, Science.

[27]  T. Williams,et al.  Mediation of increased vascular permeability after complement activation. Histamine-independent action of rabbit C5a , 1981, The Journal of experimental medicine.

[28]  E. Melby,et al.  CRC handbook of laboratory animal science , 1974 .